Acular Ls (Ketorolac Tromethamine) Patent Expiration, LOE Window & CMS Spending

Acular Ls (Ketorolac Tromethamine) by AbbVie: FDA Orange Book core substance LOE 2027-11-24, 8 AB generics, $50K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN021528 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE Date2027-11-24
Last Listed Patent or Exclusivity Date2027-11-24
Orange Book Patents (*PED Extensions)2 patents (1 *PED)
Active AB-Rated Generic Competitors8
2024 CMS Total Public Spend$50K
2024 Medicare Part D Spend$21K
2024 Medicaid Spend$29K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.